Pfizer's Delivers New Dosage Strength Hemophilia B

Pfizer Hemophilia is pleased to announce that the 3000 IU dose of BeneFIX® is now available for hemophilia B patients. BeneFIX is a recombinant coagulation factor IX product indicated for the control, prevention and perioperative management of bleeding episodes in adult and pediatric patients with hemophilia B.
Pfizer Hemophilia is the first to offer this new dosage strength for hemophilia B patients, providing reconstitution convenience for those taking 3000 IU or higher doses:
•       Comes with the same 5-mL diluent
•       May reduce the number of vials needed per infusion
•       May save space at a patient’s home or on the go
•       May have less waste for disposal
Like all other BeneFIX vial sizes, 3000 IU can be stored at room temperature or under refrigeration (2°C to 30°C/36°F to 86°F) for up to two years until expiration.
The 3000 IU dose is a new addition to the range of doses available for hemophilia B patients from Pfizer Hemophilia.
To learn more about BeneFIX, visit www.benefix.com.
What Is BeneFIX?
BeneFIX is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease.
BeneFIX is NOT used to treat hemophilia A.
Important Safety Information for BeneFIX
•       BeneFIX is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein.
•       Call your health care provider right away if your bleeding is not controlled after using BeneFIX.
•       Allergic reactions may occur with BeneFIX. Call your health care provider or get emergency treatment right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, your lips and gums turning blue, fast heartbeat, facial swelling, faintness, rash or hives.
•       Your body can make antibodies, called “inhibitors,” which may interfere with the effectiveness of BeneFIX.
•       If you have risk factors for developing blood clots, such as a venous catheter through which BeneFIX is given by continuous infusion, BeneFIX may increase the risk of abnormal blood clots. The safety and efficacy of BeneFIX administration by continuous infusion have not been established.
•       Some common side effects of BeneFIX are nausea, injection site reaction, injection site pain, headache, dizziness and rash.
Please see full Prescribing Information for BeneFIX available at www.benefix.com.